Availability of secondary prevention services after stroke in Europe: An ESO/SAFE survey of national scientific societies and stroke experts by Webb, A et al.
Original research article
Availability of secondary prevention
services after stroke in Europe: An
ESO/SAFE survey of national scientific
societies and stroke experts
AWebb1 , MR Heldner2, DAguiar de Sousa3 , EC Sandset4,5,
G Randall6, Y Bejot7, B van der Worp8, V Caso9 and U Fischer2;
On behalf of the ESO-SAFE Secondary Prevention Survey
Steering Group
Abstract
Background: Recurrent stroke is associated with increased disability and cognitive impairment, but the availability of
secondary prevention measures after transient ischaemic attack (TIA) or stroke in Europe is uncertain. This limits
prioritisation of investment and development of national stroke strategies.
Methods: National stroke representatives throughout Europe were surveyed. Consensus panels reported national data
if available, or else expert opinion, estimating the availability of each intervention by quintiles of patients, dichotomised
for analysis at 60%. Countries were classified into tertiles of gross domestic product per capita.
Results: Of 50 countries, 46 responded; 14/45 (31%) had national stroke registries and 25/46 (54.3%) had national
stroke strategies incorporating secondary prevention. Respondents reported that the majority of TIA patients were
assessed by specialist services within 48 hours in 74.4% of countries, but in nine countries more than 20% of patients
were seen after more than seven days and usually assessed by non-specialists (7/46 countries). Eighty percent of
countries deferred blood pressure assessment to primary care, whilst lifestyle management programmes were com-
monly available in only 46% of countries. Although basic interventions were widely available, interventions frequently not
available to more than 60% of patients included: ambulatory cardiac monitoring (40% countries); prescription (26%) and
continuation (46%) of statins; blood pressure control at follow-up (44%); carotid endarterectomy within one month
(15%); face-to-face follow-up in hospital (33%); direct oral anticoagulants (21%). Gross domestic product per capita and
reimbursement of interventions were the commonest predictors of availability of interventions.
Conclusions: Provision of secondary prevention varied, with gaps in care prevalent throughout Europe, particularly in
lower income countries.
Keywords
Survey, Europe, stroke, secondary prevention
Date received: 12 August 2018; accepted: 1 November 2018
1Centre for Prevention of Stroke and Dementia, University of Oxford,
Oxford, UK
2Department of Neurology, Inselspital, Bern University Hospital,
University of Bern, Bern, Switzerland
3Department of Neurosciences and Mental Health (Neurology), Hospital
de Santa Maria, University of Lisbon, Lisbon, Portugal
4Department of Neurology, Oslo University Hospital, Oslo, Norway
5Department of Research and Development, the Norwegian Air
Ambulance Foundation, Oslo, Norway
6Stroke Alliance for Europe, Brussels, Belgium
7Dijon Stroke Registry, EA7460, Pathophysiology and Epidemiology of
Cerebro-Cardiovascular diseases (PEC2), University Hospital of Dijon,
University of Burgundy, Dijon, France
8Department of Neurology and Neurosurgery, Brain Center Rudolf
Magnus, University Medical Center Utrecht, Utrecht, the Netherlands
9Santa Maria della Misericordia Hospital, University of Perugia,
Perugia, Italy
Corresponding author:
A Webb, Centre for Prevention of Stroke and Demnetia, University
of Oxford Level 6, West Wing, John Radcliffe Hospital, Oxford OX3
9DU, UK.
Email: alastair.webb@ndcn.ox.ac.uk
European Stroke Journal
0(0) 1–9
! European Stroke Organisation 2018
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/2396987318816136
journals.sagepub.com/home/eso
Introduction
Stroke causes more than one million deaths per year
and is the second commonest cause of death and the
leading cause of long-term disability in Europe.1,2 The
annual cost of stroke in Europe is estimated to be
e20 billion for direct care, e16 billion for informal
care and e9 billion due to loss of productivity.3
Recurrent major cardiovascular events occur in more
than 12% of patients over five years, even in patients
receiving excellent evidence-based treatment in affluent
countries4 and are associated with poor rehabilitation
outcomes,5 physical disability and cognitive dysfunc-
tion.6 Optimal provision of secondary prevention has
the potential to reduce recurrent events by up to 80%,3
but this requires rapid assessment, appropriate treat-
ment and ongoing follow-up to ensure efficacy and
adherence to treatments.7
Despite the morbidity, mortality and economic costs
of recurrent stroke, and the cost-effectiveness of sec-
ondary prevention,8 information regarding the provi-
sion of secondary prevention services is lacking.
Published registries focus upon acute stroke manage-
ment and hospital-based care, with limited monitoring
of ongoing secondary prevention, paralleling the clini-
cal and political focus on acute stroke.9 This lack of
published data is particularly severe in less affluent
countries in Europe, preventing national comparisons
across Europe and limiting our ability to identify tar-
gets to improve secondary prevention at the national
and international level. The European Stroke Action
Plan 2018–2030 will provide a roadmap for the devel-
opment of healthcare policy, research and stroke serv-
ices throughout Europe over the next decade, but this
requires understanding of the current state of services
and their heterogeneity across Europe. National stroke
societies are ideally placed to estimate the current pro-
vision of secondary care within each European nation,
either from national healthcare or research data or by
providing a panel of experts to estimate provision spe-
cific to their healthcare system.
Following the methodology of the recent ESO/
SAFE/ESMINT/EAN survey on provision of Acute
Stroke care,9 the European Stroke Organisation
(ESO) and the Stroke Alliance for Europe (SAFE) sur-
veyed the leaders of national stroke societies across
Europe to estimate the level of provision of secondary
prevention services.
Objectives
We aimed to estimate the availability of evidence-based
secondary prevention interventions from acute assess-
ment of TIA and minor stroke, initial treatment,
through to ongoing care to identify key gaps in care
provision across Europe, and to estimate the heteroge-
neity between nations and its determinants.
Methods
Study design and participants
This Europe-wide study of 50 countries (according to
the World Health Organization (WHO) definition of
Europe) sought consensus responses from panels of
three experts in each country, coordinated by national
stroke society chairs, or an ESO-nominated expert
where there was no national society. Coordinators
and experts (Supplementary Appendix 1) were respon-
sible for identifying the most reliable, recent national
data sources (i.e. stroke registries, healthcare data. . .)
to answer the survey questions. In the absence of
national or local stroke registries, the coordinator
and experts were asked to perform best estimates by
consensus, and took responsibility for the validity of
the responses provided.
Data collection
The survey was drafted by an ESO/SAFE steering
committee and independently reviewed by two stroke
experts (Peter Rothwell, Bo Norrving) and disseminat-
ed between 15 December 2017 and 2 February 2018
(Supplementary Appendix 2). Collected data were inde-
pendently reviewed by two authors (AJSW, MRH).
Where there was ambiguity and/or missing/conflicting
responses, the steering committee requested clarifica-
tion. Where ambiguity persisted, a single value was
taken: the mid-point of a range, the mode of multiple
respondents or the most conservative response. Related
responses were grouped into representative variables
(e.g. ‘commonest site of TIA assessment’ was derived
from percentage of patients attending each of ‘acute
admission,’ ‘stroke unit’, ‘TIA clinic’, ‘general medical
clinic’, ‘primary care’; ‘reimbursement for advanced
measures’ required reimbursement for four of: pro-
longed cardiac monitoring, PFO closure, DOACs,
novel antiplatelets, carotid stenting, left atrial append-
age closure and implantable loop recorders, with three
of carotid stenting, PFO closure, DOACs and pro-
longed monitoring).
Data analysis
The national incidence of ischaemic stroke was estimat-
ed from the Global Burden of Disease Report (2016).10
Nations were categorised into tertiles of gross
domestic product (GDP) per capita.11 Numbers of
interventional centres and procedures performed were
standardised to national population estimates in 2016.
Frequencies/rates were compared by chi-squared tests
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for categorical variables and by general linear models
for associations between continuous variables. Potential
determinants of availability of interventions included
GDP per capita (IMF 2016, International Monetary
Fund), healthcare expenditure, availability of national
stroke plans, reimbursement, number of centres.
Relationships were determined by chi-squared tests or
logistic and ordinal regression for categorical outcomes,
and general linear models for continuous outcomes.
Data were analysed in Microsoft Excel 2010 and IBM
SPSS 22.0. Chloropleth maps were drawn using https://
mapchart.net/.
Results
Of 50 countries, 46 responded of which 34 had the
survey completed by a panel of three experts, 6 by two
experts and 6 by the coordinator alone. Armenia,
Belarus, Malta, and Tajikistan did not respond despite
multiple requests. However, 32/45 (71.1% with one non-
respondent to this question) countries reported access to
some registry data, but registry characteristics varied
significantly, particularly in lower income countries
(Supplementary Appendix 3 Table 1). Stroke guidelines
were in use in the majority of countries, most commonly
ESO (38/46, 82.6%) or national stroke guidelines (38/46,
82.6%). However, 9/46 (19.6%) countries did not report
specific healthcare strategies to improve secondary
stroke prevention, either at the national or regional
level, with only 25/46 (54.3%) reporting national strat-
egies including secondary stroke prevention, more often
in the top tertile of countries by income (Supplementary
Appendix 3 Table 1).
Nearly all countries reported that standard medical
measures and interventions for secondary prevention
are reimbursed but fewer countries had reimbursement
Table 1. Availability of services to >60% of patients for after TIA or stroke, according to tertile of national income.
GDP per capita
All respondents
n (%)N
Lower tertile
n (%)
Mid-tertile
n (%)
Upper tertile
n (%) p value
TIA assessment location
Hospital 45 3 (19) 6 (40) 8 (57) 17 (38) 0.09
Stroke Team 43 3 (20) 3 (21) 7 (50) 13 (30) 0.15
TIA clinic 37 0 (0) 0 (0) 1 (7) 1 (3) 0.43
General Clinic 41 2 (13) 0 (0) 0 (0) 2 (5) 0.16
Primary Care 41 0 (0) 1 (8) 0 (0) 1 (2) 0.33
TIA assessment delay
Same Day 44 4 (25) 6 (40) 4 (31) 14 (32) 0.67
Within 48 hours 44 4 (25) 1 (7) 2 (15) 7 (16) 0.38
Within 1 week 44 2 (13) 0 (0) 3 (23) 5 (11) 0.16
>1 week 44 0 (0) 1 (7) 1 (8) 2 (5) 0.55
Carotid Imaging
Ultrasound 46 7 (44) 12 (80) 8 (53) 27 (59) 0.11
CT-angiogram 46 2 (13) 4 (27) 4 (27) 10 (22) 0.54
MR-angiogram 46 3 (19) 2 (13) 2 (13) 7 (15) 0.89
2 modalities 43 1 (7) 2 (14) 3 (20) 6 (14) 0.61
Cardiac Monitoring
ECG only 42 8 (50) 4 (31) 1 (8) 13 (31) 0.05
24–48 hours 45 6 (38) 9 (60) 7 (50) 22 (49) 0.45
>48 hours 42 0 (0) 1 (7) 2 (14) 3 (7) 0.34
BP monitoring
Primary care 41 4 (29) 8 (53) 7 (58) 19 (46) 0.25
Hospital 42 3 (23) 2 (13) 2 (14) 7 (17) 0.76
Out-of-office 39 6 (50) 5 (36) 2 (15) 13 (33) 0.18
Investigated with
TTE 45 7 (47) 8 (53) 6 (40) 21 (47) 0.77
TEE 44 0 (0) 1 (7) 1 (7) 2 (5) 0.58
TCD 44 2 (13) 4 (29) 1 (7) 7 (16) 0.26
MRA/CTA 46 2 (13) 4 (27) 7 (47) 13 (28) 0.11
Groups are compared by chi-squared tests.
N: number of responses; GDP: gross domestic product; BP: blood pressure; TTE: transthoracic echocardiography; TEE: transoesophageal echocar-
diography; TCD: transcranial ultrasound.
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for more advanced measures (left atrial appendage clo-
sure, cardiac monitoring >72 hours, implantable loop
recorders, PFO closure, direct oral anticoagulants).
Reimbursement for lifestyle management programmes
was not common, even in countries in the top tertile of
GDP (Supplementary Appendix 3 Table 1) whilst in
five lower income countries basic interventions (anti-
platelets, statins, antihypertensives, vascular imaging,
ECG) were not reimbursed. Overall, reimbursement
was more likely in the top tertile of countries by
GDP compared to the bottom two tertiles (lifestyle
management 47% vs. 14%, p¼ 0.023; DOACs 100%
vs. 63%, p¼ 0.008).
Assessment
More than 60% of patients with a TIA were assessed
by stroke specialists in higher income countries
(Table 1), but four countries in the lowest tertile of
GDP assessed >60% of patients in general medical
clinics, whilst three countries in the lower two tertiles
still deferred assessment of >20% patients to primary
care (Figure 1). In 27.8% of countries, >40% of
patients with a TIA were assessed by a non-specialist
(Supplementary Appendix 3 Table 2). In higher income
countries, assessment location varied between inpatient
admission or specialist TIA clinics (Figure 1).
Clinical guidelines in most countries recommend
assessment within 48 hours for high risk TIAs (17/19,
89%) or all events (9/11, 82%), and 10% of countries
recommend same day assessment, although 15/18
countries (83.3%) recommended assessment of low-
risk TIAs within 7 days and 3/18 countries (16.7%)
within 14 days. However, approximately 60% of coun-
tries reported seeing <20% of patients the same day
whilst only 20% of countries see more than 60% in the
same day (Supplementary Appendix 3 Figure 2).
However, nine countries saw >20% of patients in
over one week, whilst two countries took more than
one week to see most patients.
Most patients in Europe undergo carotid imaging by
ultrasound, with CTA or MRA being more common in
a few countries (Table 1), regardless of national
income. In contrast, cardiac monitoring increased
with higher income (Table 1, Supplementary
Appendix 3 Table 2), with extended monitoring signif-
icantly more common in the top tertile compared to the
lower two tertiles (p¼ 0.043). However, ECG alone is
the commonest method of assessing for AF in 40% of
countries (Figure 2). More specialist investigations
were standard (>60% patients) in some countries
but were rarely performed in others (Table 1,
Supplementary Appendix 3 Table 2). In particular,
transoesophageal echocardiography was reported to
be performed in >40% patients in six countries,
whilst TCD is readily available in seven countries
(Table 1) but is performed in <20% of patients in
25/44 (57%) of countries.
Blood pressure (BP) monitoring is standardly
deferred to primary care (Table 1) across all countries,
Figure 1. Most frequent location of assessment of patients presenting with acute TIA. Countries are coloured by the location where
respondents reported that the majority of patients with acute TIA were assessed.
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Table 2. Reported availability of treatments to >60% of patients after TIA or stroke, according to tertile of national income.
GDP per capita
All respondents
n (%)N
Lower tertile
n (%)
Mid-tertile
n (%)
Upper tertile
n (%) p value
Initial treatment includes
BP-lowering 46 16 (100) 14 (93) 10 (67) 40 (87) 0.015
Statin 46 9 (56) 11 (73) 14 (93) 34 (74) 0.06
Antiplatelet 46 15 (94) 15 (100) 14 (93) 44 (96) 0.60
Carotid intervention
<48 hours 36 0 (0) 1 (7) 1 (9) 2 (6) 0.61
<1 week 37 0 (0) 1 (7) 2 (17) 3 (8) 0.34
<2 weeks 39 0 (0) 1 (8) 5 (33) 6 (15) 0.043
<1 month 34 1 (9) 2 (15) 2 (20) 5 (15) 0.78
>1 month 33 5 (42) 0 (0) 0 (0) 5 (15) 0.006
Treatment at one year
BP measured 42 11 (69) 14 (100) 8 (67) 33 (79) 0.06
BP controlled 43 8 (50) 9 (64) 7 (54) 24 (56) 0.72
Lipids tested 42 6 (38) 12 (86) 6 (50) 24 (57) 0.024
Statin 43 7 (44) 8 (57) 8 (62) 23 (53) 0.60
Antiplatelet 43 14 (88) 14 (100) 11 (85) 39 (91) 0.33
Anticoagulant 42 7 (44) 10 (71) 7 (58) 24 (57) 0.31
DOAC 40 2 (13) 2 (14) 4 (36) 8 (20) 0.28
Follow-up method
Hospital 43 5 (36) 5 (36) 4 (27) 14 (33) 0.83
Specialist clinic 39 1 (8) 2 (17) 1 (7) 4 (10) 0.68
Primary care 43 5 (36) 7 (50) 10 (67) 22 (51) 0.25
No follow-up 37 2 (17) 0 (0) 0 (0) 2 (5) 0.11
Groups are compared by chi-squared tests.
N: number of responses to the question; GDP: gross domestic product; BP: blood pressure; TTE: transthoracic echocardiography; TEE: trans-
oesophageal echocardiography; TCD: transcranial ultrasound.
Figure 2. Reported form of monitoring used in >60% of patients to exclude atrial fibrillation in each nation.
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with only a third of countries usually performing out-
of-office monitoring. The commonest target BP was
140/90 (23/41 countries, 56.1%), whilst 14/41 countries
(34.1%) aimed for a BP below 130/80.
Management
Combined lifestyle management programmes are com-
monly available in only half of countries (22/44),
although smoking cessation and weight loss pro-
grammes are more common in the top tertile of coun-
tries by wealth (Supplementary Appendix 3 Table 1). In
contrast, the majority of patients across Europe receive
antiplatelets and antihypertensive medications at
presentation, but statins are prescribed to <60% of
patients in 26.1% of countries, particularly in lower
income countries (Table 2). These differences between
the use of different medication classes persist at one
year but with less patients taking statins, and there is
a decline in use of all agents. Despite BP and choles-
terol being recorded in the majority of patients at
follow-up, continuation of anticoagulants and control
of BP are achieved in >60% of patients in less than
60% of countries (Table 2). However, reported use of
DOACs increases in the top tertile of GDP per capita
(Table 2, Supplementary Appendix 3 Table 3).
Significant delays until carotid intervention remain
common across Europe (Figure 3), with few countries
operating within 48 hours (Austria, Cyprus) whilst five
lower income countries reported that >60% of patients
are not operated within one month (Figure 3).
Some specialist interventions were available in most
countries (Table 2), but the number of centres offering
a specific procedure increased with GDP per capita
(Figure 4).
Determinants of availability of services
GDP per capita was the sole determinant of the pro-
portion of TIA patients assessed by specialists (OR per
$1000 1.05, 1.01–1.09, p¼ 0.02), with no significant
association with health expenditure per capita, reim-
bursement for outpatient TIA clinics or availability of
national stroke strategies. Delay until TIA assessment
was not directly correlated with national income
(p¼ 0.13), but was associated with assessment by
a stroke specialist (ordinal regression OR¼ 0.58,
0.37–0.92, p¼ 0.02).
The availability of combined lifestyle modification
programmes was associated with reimbursement
(OR¼ 16.7, 1.89–146, p¼ 0.011) but was not associat-
ed with GDP per capita (p¼ 0.62). In contrast, avail-
ability of smoking cessation programmes was
non-significantly correlated with reimbursement
(OR¼ 7.8, 0.79–68.1, p¼ 0.06) but was associated
with GDP per capita, independently of reimbursement
(OR per $1000¼ 1.10, 1.03–1.18, p¼ 0.01).
Predominant use of ECG only for exclusion of atrial
fibrillation was inversely associated with national
income (OR per $1000 0.90, 0.86–0.95, p¼ 0.01) and
reimbursement (OR¼ 0.16, 0.03–0.76, p¼ 0.021), but
not with the availability of national stroke strategies
Figure 3. Reported delay until carotid intervention in >60% of patients.
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or reimbursement for other interventions. Similarly,
increased delays until carotid endarterectomy were
inversely associated with GDP per capita (OR per
$1000¼ 0.96, 0.93–0.99, p¼ 0.001), healthcare expendi-
ture per capita (OR per $1000¼ 0.76, 0.60–0.97,
p¼ 0.03) and the number of centres per million popu-
lation (OR¼ 0.73, 0.54–0.99, p¼ 0.047), but not with
the presence of national stroke strategies or reimburse-
ment for CEA (due to high levels of reimbursement).
Discussion
Despite improvements in stroke care over the past
decade,3 this estimation of current provision of second-
ary prevention identified significant reported gaps
across Europe, with limited specialist follow-up, poor
levels of adherence to medications and variable avail-
ability of advanced investigations such as prolonged
cardiac monitoring. In lower income countries,
respondents identified significant gaps in lifestyle man-
agement programmes, specialist assessment after TIA
and monitoring for atrial fibrillation beyond ECG
alone, whilst delays until assessment after TIA or treat-
ment with carotid endarterectomy are often long.
Effective secondary prevention can reduce the risk
of recurrent events by up to 80%.3 Tackling the gaps in
the provision of well-established treatments identified
in this survey could significantly improve care. For
example, respondents estimated that post-stroke
hypertension is rarely assessed by non-office-based
monitoring and treatment is often deferred to primary
care physicians, despite evidence that initiation of treat-
ment in hospital increases medication use.7 These chal-
lenges may be met by novel strategies for BP control12
and by improved specialist follow-up for patients after
cerebrovascular events, whilst increased reimbursement
could increase availability of lifestyle management pro-
grammes. In lower income countries, increasing access to
more prolonged cardiac monitoring than ECG alone may
significantly reduce the burden of recurrent events due to
AF,13 whilst expanding access to stroke specialists and
vascular surgery should result in significant improve-
ments in delays until assessment of TIAs and treatment
of carotid stenosis. However, inequalities in secondary
stroke prevention depended largely upon national
income, representing a major societal challenge. Even
here, identification of key gaps in care may enable target-
ing of limited resources to the most cost-effective inter-
ventions, including increasing availability of advanced
interventions that are cost effective (DOACs14) or likely
to be (prolonged cardiac monitoring,13 PFO closure15,16).
Where feasible, gaps in interventions may be increased
through healthcare policy, clinical guidelines and
intervention-specific reimbursement, including strategic
investment in training and development of capacity for
more technical interventions.
Some assessments were reportedly performed in the
majority of patients in some countries, but in few
Figure 4. Relationship between national wealth (GDP per capita) and the number of centres offering a specific procedure. r and
p values are derived from a univariate general linear regression.
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patients in others (transoesophageal echocardiography,
intracranial vascular imaging, TIA clinics). This partly
reflects differences in national trends (e.g. TIA clinics)7
or limited evidence for the clinical impact of some tests
(TEE, TCD), warranting a need for further research
before they can be recommended on a Europe-
wide basis.
One strength of this study is the high number of
respondents, reflecting the exceptional good-will of
contributors and repeated requests for responses.
Most respondents were leaders in national stroke soci-
eties with access to stroke registries and healthcare
administrative data or provided expert national con-
sensus opinion. However, there are limitations.
Firstly, the authors did not have access to primary reg-
istry data and many responses were estimated.
Therefore, the results are likely to be affected by opin-
ions of respondents, resulting in unintentional biases.
As such, significant differences between countries and
identified determinants of quality of provision are
indicative rather than definitive. Secondly, some
respondents felt unable to provide a reliable response
to some questions. Thirdly, we used 2016 IMF data to
estimate GDP, which may have changed since 2016.
Fourthly, multiple variables were combined into repre-
sentative variables, potentially inflating inaccuracies in
estimates. Finally, the number of centres performing
specific procedures was standardised to the reported
size of the population rather than the number of
strokes occurring in each country. However, the result-
ing estimates were compared with the equivalent esti-
mates standardised by the number of ischaemic strokes
identified in the Global Burden of Disease report
(unpublished).
This survey highlights gaps in secondary stroke pre-
vention in more and less affluent European nations,
identifying evidence-based, often cost-effective, devel-
opment targets. These can be addressed through
national and EU-wide policy initiatives, clinical guide-
lines, national and regional stroke strategies and
provision of direct reimbursement for specific interven-
tions. Although priorities in addressing these gaps will
vary between countries, this survey provides the evi-
dence to guide such priorities, focussing on interven-
tions with a strong evidence base, including rapid
assessment of TIA,7 limiting delays until carotid end-
arterectomy and maximising provision and mainte-
nance of standard medical treatments. Furthermore,
the survey demonstrated a lack of accurate healthcare
data in many countries for secondary prevention.
Establishing national and European-wide registries
for monitoring the quality of stroke care is a key chal-
lenge of the next decade, without which appropriate
policy development and targeting of research priorities
is not feasible.
Conclusions
Despite significant advances in secondary stroke pre-
vention over the past decade, many gaps in the
provision of routine, cost-effective, evidence-based
interventions across Europe remain. Through identify-
ing these gaps, the survey highlights the clinical, polit-
ical and research priorities to improve provision of
European secondary stroke prevention.
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